Tadalafil (5 mg/day or 20mg on-demand) in men with incontinence following bilateral nerve-sparing robot-assissted radical prostatectomy

Trial Profile

Tadalafil (5 mg/day or 20mg on-demand) in men with incontinence following bilateral nerve-sparing robot-assissted radical prostatectomy

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2015

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Urinary incontinence
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Mar 2012 New trial record
    • 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top